Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
Contents
1. Introduction2. Ligand-targeted particulate nanomedicines undergoing clinical evaluation 2.1. Lipid-based nanomedicines MBP-426 SGT-53 and SGT-94 MM-302 Anti-EGFR ILs-DOX 2B3-101 MCC-465 Lipovaxin-MM
2.2. Polymer-based nanomedicines BIND-014 CALAA-01 SEL-0682.3. Bacterially-derived minicells ErbituxEDVsPAC2.4. Retroviral vectors Rexin-G3. ...


雷达卡


京公网安备 11010802022788号







